Healthcare provider profile · identity verified

Daniel Evan Parecki, MD

Family Practice · BETHESDA, MD · NPI 1730618927

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	544	188
Losartan Potassium	Losartan Potassium	316	104
Amlodipine Besylate	Amlodipine Besylate	265	93
Levothyroxine Sodium	Levothyroxine Sodium	230	73
Lisinopril	Lisinopril	218	76
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	204	57
Gabapentin	Gabapentin	183	50
Trazodone Hcl	Trazodone Hcl	159	66
Metformin Hcl	Metformin Hcl	144	51
Albuterol Sulfate Hfa	Albuterol Sulfate	131	60
Rosuvastatin Calcium	Rosuvastatin Calcium	128	51
Oxycodone Hcl	Oxycodone Hcl	127	48
Simvastatin	Simvastatin	122	45
Pradaxa	Dabigatran Etexilate Mesylate	119	45
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	114	17
Tamsulosin Hcl	Tamsulosin Hcl	112	44
Metoprolol Tartrate	Metoprolol Tartrate	111	38
Furosemide	Furosemide	110	42
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	110	37
Pantoprazole Sodium	Pantoprazole Sodium	94	39
Potassium Chloride	Potassium Chloride	92	35
Atenolol	Atenolol	89	32
Glipizide	Glipizide	86	26
Omeprazole	Omeprazole	86	26
Hydrochlorothiazide	Hydrochlorothiazide	83	32
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	78	28
Terazosin Hcl	Terazosin Hcl	78	31
Duloxetine Hcl	Duloxetine Hcl	69	18
Metoprolol Succinate	Metoprolol Succinate	69	23
Mirtazapine	Mirtazapine	64	16
Allopurinol	Allopurinol	63	22
Escitalopram Oxalate	Escitalopram Oxalate	62	23
Alendronate Sodium	Alendronate Sodium	59	25
Pravastatin Sodium	Pravastatin Sodium	59	22
Fluoxetine Hcl	Fluoxetine Hcl	56	20
Meloxicam	Meloxicam	54	30
Prednisone	Prednisone	54	31
Bupropion Xl	Bupropion Hcl	52	18
Tramadol Hcl	Tramadol Hcl	52	20
Ondansetron Odt	Ondansetron	51	16
Triamcinolone Acetonide	Triamcinolone Acetonide	50	31
Metformin Hcl Er	Metformin Hcl	48	19
Spironolactone	Spironolactone	48	16
Zolpidem Tartrate	Zolpidem Tartrate	47	suppressed
Propranolol Hcl	Propranolol Hcl	46	13
Sertraline Hcl	Sertraline Hcl	46	17
Lorazepam	Lorazepam	45	19
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	44	13
Alvesco	Ciclesonide	41	16
Citalopram Hbr	Citalopram Hydrobromide	40	14
Donepezil Hcl	Donepezil Hcl	39	13
Humulin N	Insulin Nph Human Isophane	36	11
Morphine Sulfate Er	Morphine Sulfate	36	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	36	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	36	33
Wixela Inhub	Fluticasone Propion/Salmeterol	36	18
Alprazolam	Alprazolam	34	12
Quetiapine Fumarate	Quetiapine Fumarate	33	suppressed
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	33	11
Azelastine Hcl	Azelastine Hcl	32	18
Clopidogrel	Clopidogrel Bisulfate	32	12
Fluticasone Propionate	Fluticasone Propionate	32	11
Bupropion Hcl	Bupropion Hcl	31	suppressed
Fentanyl	Fentanyl	31	suppressed
Warfarin Sodium	Warfarin Sodium	31	11
Carvedilol	Carvedilol	30	11
Acyclovir	Acyclovir	28	12
Hydrocortisone	Hydrocortisone	27	16
Jardiance	Empagliflozin	27	12
Tenivac	Tetanus-Diphtheria Toxoids/Pf	26	26
Terbinafine Hcl	Terbinafine Hcl	26	13
Spiriva Respimat	Tiotropium Bromide	25	13
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	23	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	22	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	21	suppressed
Naproxen	Naproxen	21	suppressed
Pregabalin	Pregabalin	21	suppressed
Valacyclovir	Valacyclovir Hcl	21	suppressed
Baclofen	Baclofen	20	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	20	15
Eliquis	Apixaban	20	suppressed
Finasteride	Finasteride	20	suppressed
Hydralazine Hcl	Hydralazine Hcl	20	suppressed
Methocarbamol	Methocarbamol	20	suppressed
Tizanidine Hcl	Tizanidine Hcl	20	12
Estradiol	Estradiol	19	11
Famotidine	Famotidine	18	11
Nystatin	Nystatin	18	suppressed
Ropinirole Hcl	Ropinirole Hcl	18	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	17	suppressed
Montelukast Sodium	Montelukast Sodium	17	12
Ozempic	Semaglutide	17	suppressed
Testosterone Cypionate	Testosterone Cypionate	16	suppressed
Xarelto	Rivaroxaban	16	suppressed
Celecoxib	Celecoxib	15	suppressed
Dextroamphetamine Sulfate Er	Dextroamphetamine Sulfate	15	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	15	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	15	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	15	suppressed
Clonazepam	Clonazepam	14	suppressed
Buspirone Hcl	Buspirone Hcl	13	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	13	suppressed
Memantine Hcl	Memantine Hcl	13	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	12	11
Nitroglycerin	Nitroglycerin	12	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	11	suppressed
Azithromycin	Azithromycin	11	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	11	suppressed
Brilinta	Ticagrelor	11	suppressed
Cephalexin	Cephalexin	11	suppressed
Dalfampridine Er	Dalfampridine	11	suppressed
Ibuprofen	Ibuprofen	11	suppressed
Lovastatin	Lovastatin	11	suppressed
Metronidazole	Metronidazole	11	suppressed
Nifedipine Er	Nifedipine	11	suppressed
Nitrofurantoin	Nitrofurantoin Macrocrystal	11	suppressed
Rizatriptan	Rizatriptan Benzoate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error